NORWAY TRENDS AND DEVELOPMENTS Contributed by: Camilla Vislie, Magnus Hauge Greaker, Martin Guldbrandt Hansen and Nora Solberg Bjørnnes, Advokatfirmaet Thommessen AS
One significant criticism from the HOD was the NoMA’s failure to inform Novo Nordisk about its communications with the Norwegian Associa - tion for General Practice (NFA), which the NoMA had cited as supporting evidence for the deci - sion. The HOD concluded that this lack of notifi - cation violated Novo Nordisk’s right to challenge the evidence presented against it, resulting in the dismissal of the NFA’s statements in the NoMA’s evaluation. Additionally, the HOD concluded that all adver - tisements in question adhered to the Norwegian Medicinal Products Regulation, thus not consti - tuting any breach of advertising rules. Key find - ings from the HOD’s assessment are as follows. • Advertisement analysis – the HOD found that the advertisements provided adequate information aligned with product descriptions, enabling recipients to form informed opinions about the therapeutic value of the medicinal products.
• Off-label use concerns – the HOD noted that the NoMA had raised concerns regarding off- label use but failed to demonstrate a direct connection between Novo Nordisk’s adver - tisements and any such off-label use. • Imposition of penalties – given the absence of any violations of advertising regulations, the HOD determined that no penalties should be imposed on Novo Nordisk. In summary, the HOD ruled that the errors made by the NoMA significantly impacted the validity of its decision, rendering the NoMA’s decision null and void. This ruling represents a significant development in the administrative oversight of advertising regulations for medicinal products in Norway, highlighting a trend toward a more thorough examination of regulatory actions. The HOD’s decision is final. Novo Nordisk was represented by Thommessen in this matter.
216 CHAMBERS.COM
Powered by FlippingBook